A Phase I/II Study of Lapatinib Plus Myocet TM in Patients With HER2+ve Metastatic Breast Cancer Following Disease Progression During, or After, Treatment With Trastuzumab and Taxanes

Trial Profile

A Phase I/II Study of Lapatinib Plus Myocet TM in Patients With HER2+ve Metastatic Breast Cancer Following Disease Progression During, or After, Treatment With Trastuzumab and Taxanes

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Lapatinib (Primary) ; Doxorubicin liposomal
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 22 Jan 2014 Planned End Date changed from 1 Oct 2014 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
    • 24 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top